Genmab A/S
GMAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434265
No open-market purchases or sales by Genmab A/S insiders were filed in the last 90 days; 291 institutions reported holding it in 13F filings for Q2 2026, worth $2.81B in total; no superinvestor holds it.
Other share classesGNMSF
Q2 2021 vs. Q1 2021
How the institutions holding Genmab A/S changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 211 | 1 | 213 | +3 |
| Shares | 41.8M | 4.16M | 46.2M | +8.51M (+22.6%) |
| Value | $1.37B | $136.6M | $1.89B | +$659.5M (+53.6%) |
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (43)
Institutions that held Genmab A/S at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (40)
Institutions that held Genmab A/S at the end of Q1 2021 and filed for Q2 2021 without it.
Not filed for Q2 2021 yet (1)
Institutions that held Genmab A/S at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Waddell & Reed Financial Inc | 4,159,715 | $136.6M |